Minnelide™, developed by Minneamrita Therapeutics LLC, is currently undergoing a Phase 1 clinical trial aimed at establishing the maximum tolerated dose (MTD) and assessing dose-limiting toxicities (DLT) in patients with advanced gastrointestinal tumors. The market for advanced GI tumors is significant, with a growing demand for innovative therapies due to the limitations of current treatment options. If successful, Minnelide™ could position itself as a novel therapeutic agent in a competitive landscape that includes established chemotherapeutics and emerging biologics. The completion of this trial could pave the way for Phase 2 studies, enhancing investor interest and potential partnerships for further development and commercialization.